Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD). METHODS: We recruited 301 consecutive patients who had AD without CVD (mean age 71.7 years; 69.4% women; first Mini-Mental State Examination [MMSE] mean score 21.6; mean follow-up 2.3 years), who had attended a memory clinic between 1997 and 2003. VRF sought were high blood pressure, dyslipidemia, diabetes mellitus, tobacco smoking, and atherosclerotic disease. Only 21 patients (7.0%) had no VRF. Others were classified as having no VRF treated (n = 72; 25.7%), some VRF treated (n = 119; 42.5%), or all VRF treated (n = 89; 31.8%). We compared MMSE progression over time among these 3 groups using a mixed random effects regression model. RESULTS: Baseline MMSE scores were similar in the 3 groups. With adjustment for confounding factors, MMSE progression over time differed significantly between groups (p = 0.002). Patients with all their VRF treated declined less than those with none of their VRF treated. Those with some VRF treated tended to have an intermediate decline. CONCLUSIONS: In patients who have Alzheimer disease without CVD, treatment of vascular risk factors (VRF) is associated with a slower decline in Mini-Mental State Examination score. Randomized controlled trials are needed to confirm this association, but our data suggest that dementia should not prevent treatment of VRF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and may delay disease progression (Deschaintre et al., 2009), at least early in the disease course (Richard et al., 2010).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Deschaintre et al., 2009
In the citing paper
“The new 2018 NIA-AA research framework dissociates AD symptoms or phenotypes from the pathologic process.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“Of individuals age 70 years or older, 20% to 40% without cognitive impairment have biomarker or autopsy evidence of AD pathology 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“It defines AD, for research purposes, purely in terms of a biopathologic construct with the AD biomarkers of amyloid, tau, and neurodegeneration (ATN) criteria, which aids in defining the disease stages. 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Brookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00305-3 · Cited by 1,139
Hofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062
Invited Commentary: Propensity Scores
Joffe, M. M., & Rosenbaum, P. R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010011 · Cited by 1,048
(2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1069 · Cited by 988
Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics
de la Torre, J. C. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00683-0 · Cited by 834
Aggregation of vascular risk factors and risk of incident Alzheimer disease
Luchsinger, J. A., Reitz, C., Honig, L. S., Tang, M. X., Shea, S., & Mayeux, R. (2005) · Neurology · doi:10.1212/01.wnl.0000172914.08967.dc · Cited by 790
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
A Reevaluation of the Duration of Survival after the Onset of Dementia
Wolfson, C., Wolfson, D. B., Asgharian, M., M'Lan, C. E., Østbye, T., Rockwood, K., & Hogan, D. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441501 · Cited by 553
Survival after Initial Diagnosis of Alzheimer Disease
Larson, E. B., Shadlen, M.-F., Wang, L., McCormick, W. C., Bowen, J. D., Teri, L., & Kukull, W. A. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00008 · Cited by 543
Ott, A., Slooter, A., Hofman, A., van Harskamp, F., Witteman, J., Van Broeckhoven, C., van Duijn, C., & Breteler, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07541-7 · Cited by 535
Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series
Lim, A., Tsuang, D., Kukull, W., Nochlin, D., Leverenz, J., McCormick, W., Bowen, J., Teri, L., Thompson, J., Peskind, E. R., et al. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb02571.x · Cited by 451
Vascular factors predict rate of progression in Alzheimer disease
Mielke, M. M., Rosenberg, P. B., Tschanz, J., Cook, L., Corcoran, C., Hayden, K. M., Norton, M., Rabins, P. V., Green, R. C., Welsh-Bohmer, K. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000279520.59792.fe · Cited by 309
An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003
Wimo, A., Jonsson, L., & Winblad, B. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090733 · Cited by 289
Diabetes mellitus and dementia
Pasquier, F., Boulogne, A., Leys, D., & Fontaine, P. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70298-7 · Cited by 276
Self-citationVascular pathologies and cognition in a population-based cohort of elderly people
Fernando, M. S., & Ince, P. G. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.004 · Cited by 239
Disease-modifying trials in Alzheimer's disease: a European task force consensus
Vellas, B., Andrieu, S., Sampaio, C., & Wilcock, G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70677-9 · Cited by 148
Natural history of primary progressive aphasia
Le Rhun, E., Richard, F., & Pasquier, F. (2005) · Neurology · doi:10.1212/01.wnl.0000175982.57472.84 · Cited by 126
Self-citationLipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease
Masse, I. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.063388 · Cited by 125
Lee, J.-H., Olichney, J. M., Hansen, L. A., Hofstetter, C. R., & Thal, L. J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1474 · Cited by 94
Bruandet, A., Richard, F., Bombois, S., Maurage, C. A., Deramecourt, V, Lebert, F., Amouyel, P., & Pasquier, F. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.137851 · Cited by 84
Self-citationClinical Correlates and Drug Treatment of Residents With Stroke in Long-Term Care
Quilliam, B. J., & Lapane, K. L. (2001) · Stroke · doi:10.1161/01.str.32.6.1385 · Cited by 77
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics
Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., Hey-Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., et al. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.02.001 · Cited by 71
Posterior Cortical Atrophy Variants of Alzheimer’s Disease
Aharon-Peretz, J., Israel, O., Goldsher, D., & Peretz, A. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017194 · Cited by 67
Treatment for the Secondary Prevention of Stroke in Older Patients: The Influence of Dementia Status
Moroney, J. T., Tseng, C., Paik, M. C., Mohr, J. P., & Desmond, D. W. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb03839.x · Cited by 66
Cost of dementia: impact of disease progression estimated in longitudinal data
Kronborg Andersen, C., Lauridsen, J., Andersen, K., & Kragh-Sørensen, P. (2003) · Scandinavian Journal of Public Health · doi:10.1080/14034940210134059 · Cited by 44
Cognitive decline and survival in Alzheimer's disease
Wilson, R. S., Li, Y., Aggarwal, N. T., McCann, J. J., Gilley, D. W., Bienias, J. L., Barnes, L. L., & Evans, D. A. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1472 · Cited by 37
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
“onset of symptoms.(2) The new AD biological framework and the model of pathologic AD biomarkers from Jack and colleagues(18) conceptualize a progressive sequence of measurable biochemical, neurophysiological, and neuroanatomical alterations”
InfluentialThe overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557
“In support of this approach, treatment of vascular risk factors in AD patients slows down the cognitive decline [22].”
Metadata
- Authors
- Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F.
- Affiliations
- Inserm (FR)
- Venue
- Neurology
- Published
- 2009-09
- Volume
- 73
- Issue
- 9
- Pages
- 674-680
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1986968958
- Cited by
- 232
- References
- 38
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 17 · 2018: 8 · 2017: 14 · 2016: 16 · 2015: 17 · 2014: 18 · 2013: 16 · 2012: 22
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, vascular risk factors, cognitive decline, dyslipidemia, diabetes mellitus, smoking, atherosclerosis, cerebrovascular disease, Mini-Mental State Examination, dementia prevention, secondary prevention
- MeSH terms
- Aged, Alzheimer Disease, Hypolipidemic Agents, Cerebral Arteries, Intracranial Arteriosclerosis, Cerebrovascular Disorders, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Risk Factors, Risk Management, Time, Time Factors, Disease Progression, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.